Immunotherapy for pancreatic cancer - Science driving clinical progress

Research output: Contribution to journalArticle

Abstract

The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.

Original languageEnglish (US)
Pages (from-to)459-467
Number of pages9
JournalNature Reviews Cancer
Volume5
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Pancreatic Neoplasms
Immunotherapy
Immune System
Clinical Trials
Antigens
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Immunotherapy for pancreatic cancer - Science driving clinical progress. / Laheru, Daniel; Jaffee, Elizabeth.

In: Nature Reviews Cancer, Vol. 5, No. 6, 06.2005, p. 459-467.

Research output: Contribution to journalArticle

@article{32a4c427818740799c4e555db6454776,
title = "Immunotherapy for pancreatic cancer - Science driving clinical progress",
abstract = "The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.",
author = "Daniel Laheru and Elizabeth Jaffee",
year = "2005",
month = "6",
doi = "10.1038/nrc1630",
language = "English (US)",
volume = "5",
pages = "459--467",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Immunotherapy for pancreatic cancer - Science driving clinical progress

AU - Laheru, Daniel

AU - Jaffee, Elizabeth

PY - 2005/6

Y1 - 2005/6

N2 - The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.

AB - The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=20344407571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344407571&partnerID=8YFLogxK

U2 - 10.1038/nrc1630

DO - 10.1038/nrc1630

M3 - Article

C2 - 15905855

AN - SCOPUS:20344407571

VL - 5

SP - 459

EP - 467

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 6

ER -